Abstracts tagged "T Cell"

Abstract Number: 1707 • ACR Convergence 2024
TRBV9-Targeted Bispecific T Cell-Engaging Antibodies to Reset the Autoreactive T Cell Compartment in Spondyloarthritis and HLA-DQ8 Celiac Disease
Stephanie Glavaris, Alexander Pearlman, Jin Liu, Jiaxin Ge, Yuanxuan Xia, Kyle J. Kaeo, Tolulope Awosika, Colin Gliech, Tushar Nichakawade, Nikita Marcou, Chetan Bettegowda, Drew Pardoll, Kenneth W. Kinzler, Shibin Zhou, Bert Vogelstein, Suman Paul and Maximilian F. Konig, The Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Therapies that indiscriminately deplete all T cells carry a high risk of opportunistic infection, precluding their widespread use in T cell-mediated autoimmune diseases. Targeting…
Abstract Number: 1841 • ACR Convergence 2024
Preclinical Evaluation of ALLO-329: Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR for the Treatment of Autoimmune Diseases
Kristen Zhang, Joanne Li, Duy Nguyen, Nguyen Tan, Hsin-Yuan Cheng, David Huang, Suhasni Gopalakrishnan, Zachary Roberts, Cesar Sommer and Elvin Lauron, Allogene Therapeutics, South San Francisco, CA
Background/Purpose: Autologous CD19 chimeric antigen receptor (CAR) T cell therapies have recently shown to be well tolerated and highly effective in patients with autoimmune diseases…
Abstract Number: 1859 • ACR Convergence 2024
Clonal Relationships Between Tph and Tfh Cells in Patients with SLE and in Murine Lupus
Takanori Sasaki¹, John Sowerby², Yinan Xiao², Runci Wang², Pui Lee³, Yujie Qu⁴, Marc Sze⁴, Stephen Alves⁴, Marc Levesque⁴, Karen Costenbader⁵ and Deepak Rao⁶, ¹Brigham and Women's Hospital and Harvard Medical School, Brookline, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Boston Children's Hospital, Newton, MA, ⁴Merck & Co., Inc., Boston, MA, ⁵Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, ⁶Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: T helper cells, including T peripheral helper (Tph) cells and T follicular helper (Tfh) cells, play pivotal roles in promoting B cell activation and…
Abstract Number: 2530 • ACR Convergence 2024
Single-cell Multi-omics Analysis of Reactive Lymph Nodes, Affected Tissues, and Blood Reveals a Naive-like CD4+TRAIL+ T Cell Population That Differentially Directs Effector Anti-nuclear Antigen Reactive Responses in Patients with Sjogren’s Syndrome and Systemic Sclerosis
Theodoros Ioannis Papadimitriou¹, Prashant Singh², Arjan van Caam³, Madelon Vonk⁴, Irene E. van der Horst-Bruinsma⁵, Peter van der kraan³, Erik Aarntzen⁶, Martijn Huijnen⁷, Hans Koenen⁸ and Rogier Thurlings¹, ¹Radboudumc, Department of Rheumatology, Nijmegen, Gelderland, Netherlands, ²Radboudumc, Department of Medical BioSciences, Nijmegen, Netherlands, ³Radboudumc, Department of Rheumatology, Nijmegen, Netherlands, ⁴Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁵Department of Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ⁶Radboudumc, Department of Medical Imaging, Nijmegen, Netherlands, ⁷Radboudumc, Department of Medical BioSciences, Nijmegen, Gelderland, Netherlands, ⁸Radboudumc, Department of Medical Immunology, Nijmegen, Gelderland, Netherlands
Background/Purpose: Recognition of self-peptides by autoreactive CD4+ T-cells is central to the disruption of immune tolerance. Although systemic autoimmune diseases such as Sjogren’s syndrome (SjS)…
Abstract Number: 0087 • ACR Convergence 2024
SYNCAR: An Engineered IL-2/IL-2R-system That Selectively Enhances CD19 CAR T Cells to Deplete B Cells and Provide Therapeutic Benefit in SLE and RA Mouse Models Without Lymphodepletion
Ethan Jung¹, Marie semana¹, Ivan Cheng¹, Helena Silva¹, Sandro Vivona¹, Somya Singh¹, Michele Bauer¹, Mohammed Ali¹, Henry Rosas¹, Woei Chang¹, Deepti Rokkam¹, Patrick Lupardus¹, Martin Oft¹ and Paul-Joseph Aspuria², ¹Synthekine, Menlo Park, ²Sythekine, Menlo Park, CA
Background/Purpose: CD19 CAR-T therapy has demonstrated efficacy in autoimmune (AI) diseases like systemic lupus erythematosus (SLE) and lupus nephritis (LN), showing its potential beyond oncology.…
Abstract Number: 0885 • ACR Convergence 2024
Reproducible Single Cell Annotation of Programs Underlying T-cell Subsets, Activation States, and Functions
Dylan Kotliar¹, Michelle Curtis¹, Ryan Agnew¹, Kathryn Weinand¹, Aparna Nathan², Yuriy Baglaenko¹, Yu Zhao¹, Pardis Sabeti³, Deepak Rao⁴ and Soumya Raychaudhuri¹, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Broad Institute, Boston, MA, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Background/Purpose: T-cells play a key role in the pathogenesis of autoimmune disease and in protection against cancer and infection. Consequently, there is widespread interest in…
Abstract Number: 1751 • ACR Convergence 2024
Precision Targeting of Autoreactive 9G4 B Cells in Systemic Lupus Erythematosus Using Engineered Chimeric Antigen Receptor (CAR)- and Chimeric T Cell Receptor (cTCR)-T Cells
Jin Liu¹, Brian Mog¹, Yuanxuan Xia¹, Elana Shaw¹, Alexander Pearlman¹, Dylan Ferris¹, Kyle J. Kaeo¹, Colin Gliech¹, Tolulope Awosika¹, Brock Moritz¹, Tushar Nichakawade¹, Yang Li¹, Stephanie Glavaris¹, Sarah DiNapoli¹, Nikita Marcou¹, Taha Ahmedna¹, Victoria Duarte Alvarado¹, Denis Wirtz¹, Regina Bugrovsky², Scott A. Jenks², Iñaki Sanz³, Daniel Goldman⁴, Michelle Petri⁴, Chetan Bettegowda¹, Suman Paul¹, Kenneth W. Kinzler¹, Shibin Zhou¹, Felipe Andrade⁵, Bert Vogelstein¹ and Maximilian F. Konig¹, ¹The Johns Hopkins University School of Medicine, Baltimore, MD, ²Emory University School of Medicine, Atlanta, GA, ³Emory University School of Medicine, Atlanta, ⁴Johns Hopkins University School of Medicine, Timonium, MD, ⁵The Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: The autoreactive B cell compartment in systemic lupus erythematosus (SLE) is characterized by expansion of B cells expressing immunoglobulin heavy variable gene 4-34 (IGHV4-34)…
Abstract Number: 1842 • ACR Convergence 2024
Development of Next Generation CAR T Cell Therapy for the Off-the-shelf Treatment of Autoimmune Diseases Without Conditioning Chemotherapy
John Goulding¹, John Reiser², Alison O'Connor¹, Bryan Hancock¹, Jonatan Tuncel¹, Brian Groff¹, Rina Mbofung¹, Daniel Morales-Mantilla¹, Allan Williams¹, Dan Lu¹, Bi-Huei Yang¹, Eigen Peralta¹, Alma Gutierrez¹, Miguel Meza¹, Betsy Rezner¹, Amanda Sims¹, Alec Witty¹, Yijia Pan¹, Mark Jelcic¹, Shohreh Sikaroodi¹, Matthew Denholtz¹, Tom Lee¹, Anil Bagri¹, Lilly Wong¹, Jode Goodridge¹ and Bahram Valamehr¹, ¹Fate Therapeutics Inc., San Diego, CA, ²Fate Therapeutics Inc, San Diego, CA
Background/Purpose: Developed initially as a novel strategy to treat B cell malignancies, chimeric antigen receptor (CAR) T cells have now been used to treat multiple…
Abstract Number: 1860 • ACR Convergence 2024
Targeting Th1 Effector Cytokines, TNF-α and IFN-γ, Attenuates Experimental Autoimmune Myeloperoxidase ANCA Associated Vasculitis
Kei Nagai¹, Daniel Koo Yuk Cheong², Anh Cao-Le², Joshua Ooi³ and Poh Yi Gan², ¹Department of Nephrology, University of Tsukuba, Tsukuba, Ibaraki, Japan, ²Department of Medicine, Monash University, Melbourne, Victoria, Australia, ³Monash University-T Cell Therapies Research Group, Clayton, Victoria, Australia
Background/Purpose: Anti-cytokine monoclonal antibody (mAb) therapies have shown efficacy in numerous autoimmune diseases but have yet to succeed in myeloperoxidase anti-neutrophil cytoplasmic antibody associated vasculitis…
Abstract Number: 2538 • ACR Convergence 2024
HLA-DRB1 Rheumatoid Arthritis (RA) Risk Alleles Preferentially Select TRBJ2-3-containing CD4 T Cells in RA Patients
Amit Lakhanpal¹, Kazuyoshi Ishigaki², Anvita Singaraju¹, Alejandro Kochen³, Miriam Fein¹, Soumya Raychaudhuri⁴ and Laura Donlin¹, ¹Hospital for Special Surgery, New York, NY, ²Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan; Keio University Human Biology-Microbiome-Quantum Research Center (WPI-Bio2Q);; Laboratory for Human Immunogenetics, Riken Center for Integrative Medical Sciences, Bunkyo-ku, Tokyo, Japan, ³Yale School of Medicine, New Haven, CT, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: The largest genetic risk factor for RA localizes to the MHC Class II HLA-DRB1 gene, which encodes the machinery for antigen presentation to CD4…
Abstract Number: 0093 • ACR Convergence 2024
Overexpression of Epidermal Ifnk Promotes Systemic CD8+ T Cell Maturation After UV-exposure
Benjamin Klein¹, Kelsey E. McNeely², Debbie Colesa², Yiqing Gao², Nguyen Thi Kim Nguyen², Johann Gudjonsson¹ and J. Michelle Kahlenberg¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan Michigan Medicine, Ann Arbor, MI
Background/Purpose: Skin involvement is the most common organ manifestation in systemic lupus erythematosus (SLE), and exacerbation of cutaneous lupus (CLE) can precede systemic disease flares.…
Abstract Number: 0892 • ACR Convergence 2024
Peptides from Candidate Sjögren’s Disease Autoantigens and Salivary Gland Tissue-Enriched Proteins Eluted from Human Salivary Gland HLA-DR
Tommi C. Taylor¹, Sri Ramarathinam², Shan Zou Chung², Kirti Pandey², Ananth Aditya Jupudi¹, Bhuwan Khatri³, Sherri Longobardi³, Charmaine Lopez-Davis³, Astrid Rasmussen³, Kiely Grundahl³, Robert Hal Scofield³, Christopher Lessard³, Linda F. Thompson³, Anthony W. Purcell² and A. Darise Farris³, ¹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Monash University, Clayton, Victoria, Australia, ³Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Sjögren’s Disease (SjD) is characterized by aberrant autoimmune reactions in lacrimal and salivary glands (SG) leading to severe dryness. Evidence for B cell help…
Abstract Number: 1752 • ACR Convergence 2024
T Cell-Engaging Bispecific Antibodies to Target Autoreactive 9G4 Idiotope B Cells in Systemic Lupus Erythematosus
Jin Liu¹, Yuanxuan Xia¹, Dylan Ferris¹, Elana Shaw¹, Brian Mog¹, Alexander Pearlman¹, Brock Moritz¹, Kyle J. Kaeo¹, Colin Gliech¹, Tolulope Awosika¹, Sarah DiNapoli¹, Tushar Nichakawade¹, Yang Li¹, Jiaxin Ge¹, Stephanie Glavaris¹, Nikita Marcou¹, Taha Ahmedna¹, Regina Bugrovsky², Scott A. Jenks², Chetan Bettegowda¹, Daniel Goldman³, Michelle Petri³, Iñaki Sanz⁴, Kenneth W. Kinzler¹, Shibin Zhou¹, Bert Vogelstein¹, Suman Paul¹, Felipe Andrade⁵ and Maximilian F. Konig¹, ¹The Johns Hopkins University School of Medicine, Baltimore, MD, ²Emory University School of Medicine, Atlanta, GA, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴Emory University School of Medicine, Atlanta, ⁵The Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Chimeric antigen receptor (CAR)-T-cell therapies hold promise for systemic lupus erythematosus (SLE) but are critically limited by scalability and long-term safety (e.g., risk of…
Abstract Number: 1843 • ACR Convergence 2024
Immune Responses to Herpes Zoster Vaccine Responses in Rheumatic Patients on JAK Inhibitors: Insights in Humoral and Cellular Response
cristiana sieiro santos¹, Juan Garcia Herrero², Jose Ordas Martínez³, Alejandra López Robles⁴, Carolina Álvarez Castro⁴, Ronald Colindres⁴, Estefanía Robles Martin⁴, Ana María Sahagún⁵ and Jose María Ruiz de Morales⁴, ¹Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ²Complejo Asistencial Universitario de León, León, Castilla y Leon, Spain, ³Complejo Asistencial Universitario de Leon, Leon, ⁴Complejo Asistencial Universitario de León, León, Spain, ⁵University of Leon, León, Spain
Background/Purpose: Patients with immune-mediated rheumatic diseases treated with JAK inhibitors face an elevated risk of herpes zoster (HZ) infection. Shingrix, a recombinant inactive vaccine, offers…
Abstract Number: 1861 • ACR Convergence 2024
CD8T Cells Depletion Promotes Human Tph/Tfh Cells Proliferation and Sjogren Syndrome Like Symptoms Without Graft versus Host Diseases in PBMC Transferred-humanized Mice
Yuzo Koda¹, Piruzyan Mariam¹, Sota Fujimori¹, Ryota Sato² and Sayuka Kato¹, ¹Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan, ²Mitsubishi Tanabe Pharma Corporation, Brighton, MA
Background/Purpose: Peripheral helper T (Tph) and follicular helper T (Tfh) cells are known to play a central role in the interaction between T and B…

« Previous Page
1
…
4
5
6
7
8
…
21
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].